Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

562
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
562

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta-analysis and meta-regression.

Addiction (Abingdon, England)·2026
Same author

Sexual minority (LGBQ+) women's experiences of accessing addiction services: a qualitative study.

Frontiers in public health·2026
Same author

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).

Journal of affective disorders·2026
Same author

Characteristics of deaths due to drug-related causes among individuals recently released from prison in the United Kingdom, 1997-2025.

Addiction (Abingdon, England)·2026
Same author

Barriers and facilitators to accessing addiction treatment services for sexual minority (LGBQ+) people: systematic review.

The British journal of psychiatry : the journal of mental science·2026
Same author

Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.

Journal of psychopharmacology (Oxford, England)·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Jan 27, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.2K

Memantine for dementia.

Rupert McShane1, Maggie J Westby, Emmert Roberts

  • 1Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Level 4, Main Hospital, Room 4401C, Oxford, Oxfordshire, UK, OX3 9DU.

The Cochrane Database of Systematic Reviews
|March 21, 2019
PubMed
Summary
This summary is machine-generated.

Memantine offers a small benefit for moderate-to-severe Alzheimer's disease (AD), but shows no significant efficacy in mild AD. Further long-term studies are needed to confirm its sustained benefits and safety in different stages of dementia.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.8K
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

1.4K

Related Experiment Videos

Last Updated: Jan 27, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.2K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.8K
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

1.4K

Area of Science:

  • Neuroscience and Pharmacology
  • Clinical Trials and Evidence Synthesis
  • Geriatric Medicine

Background:

  • Memantine, an NMDA receptor antagonist, is approved for moderate-to-severe Alzheimer's disease (AD) and used off-label for mild AD.
  • Understanding the efficacy and safety of memantine across different dementia severities is crucial for clinical practice.

Purpose of the Study:

  • To evaluate the efficacy and safety of memantine in individuals with dementia.
  • To determine if memantine provides additional benefits when used concurrently with cholinesterase inhibitors (ChEIs).

Main Methods:

  • Systematic review and meta-analysis of double-blind, placebo-controlled, randomized trials of memantine in dementia.
  • Data pooled from 44 trials involving nearly 10,000 participants, with a focus on Alzheimer's disease (AD).
  • Analyses stratified by dementia severity (mild vs. moderate-to-severe AD) and concomitant ChEI use.

Main Results:

  • Moderate-to-severe AD: Small clinical benefits observed for cognitive function, global impression, daily living activities, and behavior/mood, irrespective of ChEI use.
  • Mild AD: Probable lack of significant difference between memantine and placebo in cognitive function, daily living activities, and behavior/mood.
  • Adverse events: No significant difference in overall adverse events; memantine may increase treatment discontinuation in mild AD and is associated with increased dizziness.

Conclusions:

  • Memantine demonstrates a small clinical benefit in moderate-to-severe AD but lacks efficacy in mild AD.
  • Current evidence does not support the off-label use of memantine in mild AD, despite common practice.
  • Long-duration trials are needed to assess sustained benefits and long-term safety in both mild and moderate-to-severe AD.